FMC (US:FMC)2026-02-05 15:00Financial Data and Key Metrics Changes - In Q4 2025, FMC reported sales of $1.08 billion, an 11% decline year-over-year, or a 5% decline on a like-for-like basis excluding India [16] - Adjusted EBITDA for Q4 was $280 million, down 17% year-over-year, and adjusted EPS was $1.20, a 33% decline [17] - Free cash flow for Q4 was $623 million, with GAAP cash from operations of $657 million, up $230 million from the prior year [17][18] - The company ended 2025 with net debt of approximately $3.5 billion, down over $550 million from the third quarter [18] Business Line Data and Key Metrics Changes - Sales of the core product portfolio, excluding Rynaxypyr, were approximately $2.2 billion in 2025, with nearly $1 billion from high-cost facilities [7] - Rynaxypyr sales were just over $800 million in 2025, with expectations for generic offerings to begin in 2026 [8] - Sales of new active ingredients increased from approximately $130 million in 2024 to approximately $200 million in 2025, but fell short of the $250 million expectation [10] Market Data and Key Metrics Changes - Price declined by 6% in Q4 due to lower Rynaxypyr prices and strong competition, particularly in Latin America [16] - The company anticipates a mid-single-digit price headwind driven by Rynaxypyr in 2026 [11] - The removal of India is expected to represent a 2% full-year headwind, impacting only the first half of 2026 [11] Company Strategy and Development Direction - The board has authorized exploring strategic options, including a potential sale of the company, while focusing on operational priorities for 2026 [5][6] - The company aims to pay down over $1 billion of debt through asset sales and licensing agreements, including the sale of its India commercial business [6] - FMC is committed to improving the competitiveness of its off-patent portfolio and driving growth of new active ingredients [6][10] Management's Comments on Operating Environment and Future Outlook - Management acknowledged challenging market conditions, including intense competition from generics and weaker grower margins [16] - The company expects 2026 to be a bottom year, with growth anticipated starting in 2027 [60][62] - Management expressed confidence in the growth portfolio and the ability to stabilize the core portfolio by addressing manufacturing costs [29][34] Other Important Information - The company is in active discussions regarding licensing agreements and asset sales, with a focus on maximizing shareholder value [5][6] - The strategic review process is at a preliminary stage, and the company has retained financial and legal advisors to assist [6] Q&A Session Summary Question: Contribution to EBITDA from different product groups - Management does not break out profitability by product line but emphasizes that the core portfolio is a significant contributor to profitability [25][27] Question: Drivers for mid-teens EBITDA growth in 2027 and 2028 - Growth is expected from the established growth portfolio, with confidence in the continuation of trends seen in previous years [32][35] Question: Timing of strategic review and potential sale of the company - The strategic review was initiated to explore options for increasing shareholder return and improving growth potential [37][38] Question: Confidence in understanding company challenges - Management acknowledges the core portfolio's challenges and is focused on addressing them while maintaining confidence in the growth portfolio [53][55] Question: Update on debt maturities and refinancing plans - The company plans to refinance $500 million in bonds maturing in October and is focused on reducing total debt by $1 billion [64][66] Question: Factors affecting new product revenue projections - The shortfall in new product revenue is attributed to registration delays and lower-than-expected sales in Brazil [69][70]